http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20220062080-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_175bc6a075588ad56e84f22b391c7223 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-59 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-646 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-23 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-23 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-59 |
| filingDate | 2020-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5171488712d5173c27e7f8373ebed81b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4929f9a21df1637edde3d29797999c9d |
| publicationDate | 2022-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20220062080-A |
| titleOfInvention | Immunotherapy for the treatment of prostate cancer |
| abstract | The present disclosure describes GnRH therapeutics for neutralizing GnRH levels in a subject capable of attenuating or eliminating prostate cancer cell growth and/or metastasis by reducing testosterone levels. Therapeutic agents are produced synthetically. The GnRH therapeutic agent comprises a GnRH peptide and a hapten carrier (hC) comprising a separately synthesized monomeric peptide (MP), and then, after self-assembly of the hC, the GnRH is covalently bound to form a GnRH-hC conjugate that can function as a therapeutic agent. do. MP contains heptad repeats that follow a specific pattern. hCs can include GnRH peptides attached to monomeric peptides prior to self-assembly to form therapeutic agents. Optionally, the GnRH-hC conjugate further comprises one or more T-cell epitopes at the N- and/or C-terminus of the one or more amphiphilic alpha helices. The present disclosure also describes compositions comprising an immunogenic composition comprising a therapeutic agent described herein. |
| priorityDate | 2019-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 536.